Results 281 to 290 of about 245,988 (303)

Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma

Annals of Oncology, 2020
Victor Moreno, María Vieito, J M Sepulveda   +2 more
exaly  

The Transcription Factor T-bet Resolves Memory B Cell Subsets with Distinct Tissue Distributions and Antibody Specificities in Mice and Humans

Immunity, 2020
David H Canaday, Jinfang Zhu, Aaron Rosenfeld   +2 more
exaly  

THE ECONOMICS OF SPORTS BETTING AND SPORTS BETTING IN ECONOMICS

2021
Gomez Gonzalez, Carlos, del Corral, Julio   +1 more
openaire   +2 more sources

Investment in Cancer Control and Research: A Sure Bet†

Ca-A Cancer Journal for Clinicians, 2006
Carolyn D Runowicz
exaly  

Make your best BET: The emerging role of BET inhibitor treatment in malignant tumors

Pharmacology & Therapeutics, 2020
Patrick Schöffski, Oliver Bechter
exaly  

Human T-bet Governs Innate and Innate-like Adaptive IFN-γ Immunity against Mycobacteria

Cell, 2020
Cindy S Ma, Fatima Al Ali, Jean-Marc Doisne   +2 more
exaly  

To Bet or Not To Bet:

2018
openaire   +1 more source

Evaluation of the BET Theory for the Characterization of Meso and Microporous MOFs

Small Methods, 2018
Xia Zhang, Thomas J. Macdonald, Filip Ambroz   +2 more
exaly  

T-bet Transcription Factor Promotes Antibody-Secreting Cell Differentiation by Limiting the Inflammatory Effects of IFN-γ on B Cells

Immunity, 2019
Christopher D Scharer, Ravi S Misra, Sara L Stone   +2 more
exaly  

The Transcription Factor T-bet Limits Amplification of Type I IFN Transcriptome and Circuitry in T Helper 1 Cells

Immunity, 2017
Yohei Mikami, Yuka Kanno, Takeshi Kawabe
exaly